Lunit Presents 5 Research Abstracts at European Society for Medical Oncology Congress

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit announced on the 17th that it will present five research abstracts related to AI biomarkers in poster sessions at the 2022 European Society for Medical Oncology (ESMO 2022), held in Paris, France from the 9th to the 13th of next month. ESMO is the largest cancer academic conference in Europe, with more than 25,000 members including cancer specialists and global pharmaceutical and biotech experts from over 160 countries worldwide. It is considered one of the world's top three cancer societies alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).

All five abstracts present research results related to the AI biomarker platform and AI pathology analysis solution, 'Lunit SCOPE.' The research covers various models of Lunit SCOPE, including ▲Lunit SCOPE IO ▲Lunit SCOPE PD-L1 ▲Lunit SCOPE HER2 ▲Lunit SCOPE Tumor Purity.

Lunit will also set up a dedicated booth at the ESMO conference site to showcase the practical use of various Lunit SCOPE models and provide product demonstrations.

Seobeom Seok, CEO of Lunit, said, "We continue to confirm the clinical value of Lunit SCOPE at various global cancer conferences," adding, "It is a meaningful opportunity to introduce the advanced research results of Lunit SCOPE, with five abstracts selected for poster presentations at this ESMO as well."

This content was produced with the assistance of AI translation services.